{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
Bacitracin Methylene Disalicylate Feed Grade by Lifecome Biochemistry Co., Ltd
(2015)
Source URL:
First approved in 2015
Source:
Bacitracin Methylene Disalicylate Feed Grade by Lifecome Biochemistry Co., Ltd
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Possibly Marketed Outside US
Source:
M020
(2015)
Source URL:
First approved in 2015
Source:
M020
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
Diceplon by Yoshitomi Pharmaceutical Industries
Source URL:
First approved in 2015
Source:
21 CFR 343
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Spiclomazine induces apoptosis associated with the suppression of migration and invasion in pancreatic carcinoma cells
Status:
Possibly Marketed Outside US
Source:
DERAMAXX (deracoxib) by Searle
Source URL:
First approved in 2015
Source:
NADA141203
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Deracoxib (trade name Deramaxx, Novartis) is a non-steroidal anti-inflammatory drug of the coxib class, used in veterinary medicine for the control of postoperative pain and inflammation associated with orthopedic and dental surgery and for the control of pain and inflammation associated with osteoarthritis in dogs. Data indicate that deracoxib inhibits the production of PGE1 and 6-keto PGF1 by its inhibitory effects on prostaglandin biosynthesis. Deracoxib was shown to have antitumor effect against transitional cell carcinoma of the urinary bladder.
Status:
Possibly Marketed Outside US
Source:
21 CFR 347
(2015)
Source URL:
First approved in 2015
Source:
21 CFR 347
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 348
(2018)
Source URL:
First approved in 2015
Source:
21 CFR 348
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
LAUROCAPRAM is a percutaneous permeation enhancer facilitating absorption of different chemicals upon their application to the skin. Its enhancing effect is associated with different mechanisms: incorporation of its dodecyl group into the lipid bilayer, an increase of the motion of the alkylic chains of lipids, and lipid fluidization.
Status:
Possibly Marketed Outside US
Source:
21 CFR 333E
(2015)
Source URL:
First approved in 2015
Source:
21 CFR 333E
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
FORTE Magnetic S3 Oil Control Anti-Dandfuff by FORMOSA BIOMEDICAL TECHNOLOGY CORPORATION
(2024)
Source URL:
First approved in 2015
Source:
21 CFR 358B
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2015)
Source URL:
First approved in 2015
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Status:
Possibly Marketed Outside US
Source:
TECHNESCAN
Source URL:
First approved in 2015
Source:
NDA018321
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Skeletal imaging, radionuclide—Technetium Tc 99m oxidronate is indicated as a skeletal imaging agent in adults and children to delineate areas of abnormal osteogenesis, such as those that occur with metastatic bone disease, Paget's disease, arthritic disease, osteomyelitis, and fractures. Technetium Tc 99m oxidronate injection is a radiopharmaceutical. Exact mechanism is not known. It is generally accepted that technetium Tc 99m oxidronate localizes on the surface of hydroxyapatite crystals by a process termed chemisorption, with blood flow and/or blood concentration being most important in the delivery of the agent to sites of uptake. Visualization of osseous lesions is possible since skeletal uptake of technetium Tc 99m oxidronate is altered in areas of abnormal osteogenesis. Rapidly distributed in and cleared from blood after intravenous administration, with about half the dose normally accumulating in the skeleton within 3 to 4 hours after injection. May also locate within infarcted myocardial cells or other regions of soft tissue necrosis or calcification. Minimal uptake by soft-tissue organs, except calcified cartilage, blood vessels, and kidneys. TechneScan HDP exhibits its greatest affinity for areas of altered osteogenesis and actively metabolizing bone. Some hypersensitivity reactions, as well as nausea and vomiting, have been infrequently associated with Technetium Tc 99m Oxidronate.